Pharmacogenetics of coumarin dosing: Prevalence of CYP2C9 and VKORC1 polymorphisms in the lebanese population

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 11, 2011, Pages 827-830

  Djaffar Jureidini, Isabelle ^a   Chamseddine, Nabil ^a   Keleshian, Sose ^a   Naoufal, Rania ^a   Zahed, Laila ^a   Hakime, Noha ^a  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME P450 2C9; GENOMIC DNA; MENADIONE EPOXIDE REDUCTASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LEBANON; MALE; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETIC PARAMETERS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; FEMALE; GENE FREQUENCY; HUMANS; INTERNATIONAL NORMALIZED RATIO; LEBANON; MALE; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 81755172154     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0248     Document Type: Article

References (19)

1. Barbour B, Salameh P (2009) Consanguinity in Lebanon: prevalence, distribution and determinants. J Biosoc Sci 41:505-517.
2. Becattini C, Lignani A, Agnelli G (2010) New anticoagulants for the prevention of venous thromboembolism. Drug Design Dev Ther 4:49-60.
3. Brian G (2006) Pharmacogenetics-based coumarin therapy. He-matology 1:467-473.
4. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. (2005) A polymorphism in the VKORC1 Gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649. (Pubitemid 40070748)
5. Deepak V, Mc Leod ML, Eby C, et al. (2005) The pharmacoge-netics of coumarin therapy. Future Med 6:503-513.
6. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA (2006) In-terethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphismsinhealthyindividuals. Mol DiagnTher 10:29-40.
7. Geisen C, Watza M, Sittinger K, et al. (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94:773-799.
8. Inhorm MC, Kobeissi L, Nassar Z, et al. (2009) Consanguinity and family clustering of male factor infertility in Lebanon. Fertil Steril 91:1104-1109.
9. The International Warfarin Pharmacogenetics Consortium (2009) Estimation of the warfarin dose with clinical and pharmaco-genetic data. N Engl J Med 360:753-764.
10. Limdi NA, Beasley TM, Crowley MO, et al. (2008) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9:1445-1458.
11. Oldenburg J, Watzka M, Rost S, et al. (2007) VKORCI: Molecular target of coumarins. J Thromb Haemost 5:1-6.
12. Press release of the FDA (August 16, 2007a) FDA approves updated warfarin (Coumadin) prescribing information. Available at www.fda.gov/bbs/topics/NEWS/ 2007/NEW01684.html (accessed February 11, 2008).
13. Press release of the FDA (September 17, 2007b) FDA clears genetic lab test for warfarin sensitivity. Available at www.fda.gov/bbs/topics/NEWS/2007/ NEW01701.html (accessed February 11, 2008).
14. Sanchez-Diz P, Estany-Gestal A, Aguirre C, et al. (2009) Prevalence of CYP2C9 polymorphisms in the South of Europe. Pharmacogenomics J 9:306-310.
15. TM systematic review and meta-analysis. Genet Med 7:97-104. (Pubitemid 40261834)
16. Schwarz UI, Ritchie MD, Bradford Y, et al. (2008) Genetic determinants of response to warfarin during initial antic-oagulation. N Engl J Med 358:999-1008. (Pubitemid 351347099)
17. 359 allelic variantin the tolbutamide polymorphism. Pharmacogenetics 6:341-349. (Pubitemid 26288624)
18. Wahlund S (1928) Zusammensetzung von populationen und korrelationsercheinungen vom standpunkt der vererbung-slehre aus betrachtet. Hereditas 11:65-106.
19. Wang SL, Huang JD, Lai MD, Tsai JJ (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42.